Multidrug resistant Tuberculosis

dc.contributor.author	Elhashmy, Hadeel
dc.date.accessioned	2019-06-25T09:04:01Z
dc.date.available	2019-06-25T09:04:01Z
dc.date.issued	2019-04-01
dc.identifier.uri	http://repository.limu.edu.ly/handle/123456789/932
dc.description	Tuberculosis remains a major cause of morbidity and mortality globally, one of the causes are multidrug resistant tuberculosis (MDR-TB). MDR-TB refers to tuberculosis that is resistant to both rifampicin and isoniazid. Almost 20% of all TB strains worldwide are resistant to at least one major TB drug, approximately 10% are isoniazid monoresistant . Multidrug resistant tuberculosis with additional resistance to any fluoroquinolone (such as ofloxacin or moxifloxacin) and also any one of the three second line injectable agents (amikacin, capreomycin,kanamycin)is designated as extensively drug resistant tuberculosis (1). Rapid diagnosis and effective treatment are two of the most important strategies tuberculosis(TB)control program to prevent ongoing transmission of disease and to improve patient outcomes	en_US
dc.language.iso	en	en_US
dc.publisher	faculty of Basic Medical Science - Libyan International Medical University	en_US
dc.rights	Attribution 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/us/	*
dc.title	Multidrug resistant Tuberculosis	en_US
dc.type	Other	en_US

Except where otherwise noted, this item's license is described as Attribution 3.0 United States